8legs: Eli lilly and company

Your Followed Topics

#1 out of 3

Weight loss jab users face questions over why a 'golden dose' has been removed and whether effectiveness will drop.
Experts warn removal may affect how well the injections work for some people.
The report links the discussion to Mounjaro and related weight-management medicines.
Readers are informed about ongoing concerns and real-world reactions to the change.
The article notes that news outlets are reporting multiple recent developments around the jab.
A report segment emphasizes that the debate includes safety and regulatory perspectives.
The piece mentions ongoing public interest in Comet 3I/Atlas as a separate news topic in the same feed.
The article attributes the coverage to a group of health, science, and lifestyle topics.
Context is provided about user experiences and the potential impact of dose changes.
The report signals that current headlines are part of a broader discussion on weight loss solutions.

Vote 0

#2 out of 3

Novo Nordisk shares fell after a U.S. pricing deal for GLP-1 drugs, including Wegovy, was announced.
The FDA granted a voucher to speed Wegovy’s review, with potential approval by year-end.
In India, Wegovy trailed Mounjaro in 2025 dose sales, highlighting competitive pressure.
The report mentions Wegovy’s competition from Eli Lilly’s drug in the market landscape.

Vote 0

#3 out of 3

Latest development shows Mounjaro gaining rapid uptake in India as a weight-loss option among affluent patients.
The drugs, used to treat diabetes, have become India’s most valued medicine by monthly sales in October, signaling strong demand.
Regulators have approved Ozempic and related drugs for diabetes in India, not obesity, affecting how clinicians frame use for weight loss.
Doctors warn that lifestyle changes are crucial, though injections can seem easier for patients seeking rapid results.
High monthly costs limit access to these drugs, with some patients spending over $100 monthly on alternatives like Rybelsus.
Experts attribute rising diabetes and obesity in India to Western-style diets and urban lifestyles.
Some patients report substantial weight loss, while doctors caution about long-term dependence on injections.
Industry insiders anticipate generic competition after patent expiry.
Medical professionals stress combining medications with lifestyle changes to sustain results.
The article highlights the gap between diabetes treatment costs and affordability in India.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.